Publications médicales – 2020-2021

 

  1. Lamarca A, Cives M, de Mestier L, et al. Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment. World J Gastroenterol 2021; 27: 976–989.

  2. De Rycke O, Walter T, Perrier M, et al. Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer 2021; 28: 457–466.

  3. Kaune T, Ruffert C, Hesselbarth N, et al. Analysis of GPRC6A variants in different pancreatitis etiologies. Pancreatology 2020; 20: 1262–1267.

  4. Dawod M, Gordoa TA, Cives M, et al. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. Curr Treat Options Oncol 2021; 22: 73.

  5. Vullierme M-P, Ruszniewski P, de Mestier L. Are recist criteria adequate in assessing the response to therapy in metastatic NEN? Rev Endocr Metab Disord 2021; 22: 637–645.

  6. Lacombe C, De Rycke O, Couvelard A, et al. Biomarkers of Response to Etoposide-Platinum Chemotherapy in Patients with Grade 3 Neuroendocrine Neoplasms. Cancers (Basel) 2021; 13: 643.

  7. Girodon E, Rebours V, Chen JM, et al. Clinical interpretation of PRSS1 variants in patients with pancreatitis. Clin Res Hepatol Gastroenterol 2021; 45: 101497.

  8. Girodon E, Rebours V, Chen JM, et al. Clinical interpretation of SPINK1 and CTRC variants in pancreatitis. Pancreatology 2020; 20: 1354–1367.

  9. Perrier M, Hentic O, Walter T, et al. Clinical usefulness of FDG-PET for management of well-differentiated digestive neuroendocrine tumors. Dig Liver Dis 2020; 52: 1521–1524.

  10. Ambrosini V, Kunikowska J, Baudin E, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer 2021; 146: 56–73.

  11. Tannoury J, de Mestier L, Hentic O, et al. Contribution of Immune-Mediated Paraneoplastic Syndromes to Neurological Manifestations of Neuroendocrine Tumours: A Retrospective Study. Neuroendocrinology 2021; 111: 123–128.

  12. Lotfalizadeh E, Ronot M, Wagner M, et al. Correction to: Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging. Eur Radiol 2020; 30: 6387.

  13. Tobaly D, Santinha J, Sartoris R, et al. CT-Based Radiomics Analysis to Predict Malignancy in Patients with Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Cancers (Basel) 2020; 12: E3089.

  14. Mikail N, Pisani A, El Hatimi S, et al. Early Diagnosis and Treatment of Myocardial Neuroendocrine Tumor Metastasis: The Cornerstone Role of Multimodality Imaging. Circ Cardiovasc Imaging 2021; 14: e011857.

  15. Pignon F, Turpin A, Hentic O, et al. Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma. Pancreatology 2021; S1424-3903(21)00157–5.

  16. Brugel M, Walter T, Goichot B, et al. Efficacy of treatments for VIPoma: A GTE multicentric series. Pancreatology 2021; S1424-3903(21)00524-X.

  17. Gaujoux S, Parvanescu A, Fusco G, et al. Familial Pancreatic Intraductal Papillary and Mucinous Neoplasms Do Not Carry Constitutional or Postzygotic GNAS Activating Mutations. Pancreas 2021; 50: e14–e15.

  18. Dokmak S, Tetart A, Aussilhou B, et al. French reconnection: A conservative pancreato-enteric reconnection for disconnected pancreatic duct syndrome. Pancreatology 2021; 21: 282–290.

  19. Aguilera Munoz L, de Mestier L, Lamallem H, et al. Gastrointestinal bleeding in patients with pancreatic cancer: Causes and haemostatic treatments. United European Gastroenterol J 2020; 8: 1106–1114.

  20. Naudin S, Viallon V, Hashim D, et al. Healthy lifestyle and the risk of pancreatic cancer in the EPIC study. Eur J Epidemiol 2020; 35: 975–986.

  21. Merola E, Zandee W, de Mestier L, et al. Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference? Neuroendocrinology 2021; 111: 170–177.

  22. Moussiegt A, Müller R, Ebbo M, et al. IgG4-related disease and hypereosinophilic syndrome: Overlapping phenotypes. Autoimmun Rev 2021; 20: 102889.

  23. Strosberg J, Kunz PL, Hendifar A, et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging 2020; 47: 2372–2382.

  24. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study – PubMed, https://pubmed.ncbi.nlm.nih.gov/33052555/ (accessed 29 August 2021).

  25. Gay-Chevallier S, de Mestier L, Perinel J, et al. Management and Prognosis of Localized Duodenal Neuroendocrine Neoplasms. Neuroendocrinology 2021; 111: 718–727

  26. Partelli S, Ramage JK, Massironi S, et al. Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study. Front Med (Lausanne) 2020; 7: 598438.

  27. Vinault S, Mariet A-S, Le Bras M, et al. Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1: A GTE and AFCE Cohort Study (Groupe d’étude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne). Ann Surg 2020; 272: 1094–1101.

  28. Vullierme M-P, Gregory J, Rebours V, et al. MRI is useful to suggest and exclude malignancy in mucinous cystic neoplasms of the pancreas. Eur Radiol. Epub ahead of print 10 August 2021. DOI: 10.1007/s00330-021-08091-6.

  29. De Rycke O, Védie A-L, Guarneri G, et al. O-positive blood type is associated with prolonged recurrence-free survival following curative resection of pancreatic neuroendocrine tumors. Pancreatology 2020; 20: 1718–1722.

  30. Dermine S, Lévi-Strauss T, Abou Ali E, et al. Organ Preservation after Endoscopic Resection of Early Esophageal Cancer with a High Risk of Lymph Node Involvement. Cancers (Basel) 2020; 12: E3598.

  31. Girot P, Baudin E, Senellart H, et al. Oxaliplatin and 5-fluorouracil (FOLFOX) in advanced well differentiated digestive neuroendocrine tumors: a multicenter national retrospective study from the French Group of Endocrine Tumors (GTE). Neuroendocrinology. Epub ahead of print 26 July 2021. DOI: 10.1159/000518650.

  32. Hammel P, Zhang C, Matile J, et al. PARP inhibition in treatment of pancreatic cancer. Expert Rev Anticancer Ther 2020; 20: 939–945.

  33. Porta M, Gasull M, Pumarega J, et al. Plasma concentrations of persistent organic pollutants and pancreatic cancer risk. Int J Epidemiol 2021; dyab115.

  34. de Mestier L, Savagner F, Brixi H, et al. Plasmatic and Urinary 5-Hydroxyindolacetic Acid Measurements in Patients With Midgut Neuroendocrine Tumors: A GTE Study. J Clin Endocrinol Metab 2021; 106: e1673–e1682.

  35. Deleval N, Pesque L, Dieudonné A, et al. Prognostic impact of bone metastases detected by 18F-DOPA PET in patients with metastatic midgut neuroendocrine tumors. Eur Radiol 2021; 31: 4166–4174.

  36. Guarneri G, de Mestier L, Landoni L, et al. Prognostic Role of Examined and Positive Lymph Nodes after Distal Pancreatectomy for Non-Functioning Neuroendocrine Neoplasms. Neuroendocrinology 2021; 111: 728–738.

  37. Diedisheim M, Dermine S, Jouinot A, et al. Prognostic transcriptome classes of duodenopancreatic neuroendocrine tumors. Endocr Relat Cancer 2021; 28: 563–571.

  38. de Mestier L, Cadiot G. Rectal neuroendocrine tumors: is it all on first sight? Endoscopy 2021; 53: 710–712.

  39. Legoux J-L, Lombard-Bohas C, Brixi H, et al. Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study. Clin Res Hepatol Gastroenterol 2021; 45: 101572.

  40. Dioguardi Burgio M, Cros J, Panvini N, et al. Serotonin immunoreactive pancreatic neuroendocrine neoplasm associated with main pancreatic duct dilation: a recognizable entity with excellent long-term outcome. Eur Radiol. Epub ahead of print 11 May 2021. DOI: 10.1007/s00330-021-08007-4.

  41. Hedjoudje A, Farha J, Cheurfa C, et al. Serum phosphate is associated with mortality among patients admitted to ICU for acute pancreatitis. United European Gastroenterol J 2021; 9: 534–542.

  42. Merola E, Alonso Gordoa T, Zhang P, et al. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%? Oncologist 2021; 26: 294–301.

  43. Yao JC, Strosberg J, Fazio N, et al. Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. Endocr Relat Cancer 2021; ERC-20-0382.R1.

  44. Cros J, Théou-Anton N, Gounant V, et al. Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid Morphology. Neuroendocrinology 2021; 111: 158–169.

  45. Sokal A, Chawki S, Nguyen Y, et al. Specificities of acute cholangitis in patients with cancer: a retrospective comparative study of 130 episodes. Eur J Clin Microbiol Infect Dis. Epub ahead of print 20 August 2021. DOI: 10.1007/s10096-021-04289-0.

  46. Masson E, Rebours V, Buscail L, et al. The reversion variant (p.Arg90Leu) at the evolutionarily adaptive p.Arg90 site in CELA3B predisposes to chronic pancreatitis. Hum Mutat 2021; 42: 385–391.

  47. Ewers M, Canaff L, Weh AE, et al. The three common polymorphisms p.A986S, p.R990G and p.Q1011E in the calcium sensing receptor (CASR) are not associated with chronic pancreatitis. Pancreatology 2021; S1424-3903(21)00531–7.

  48. de Mestier L, Lamarca A, Hernando J, et al. Treatment outcomes of advanced digestive well-differentiated grade 3 NETs. Endocr Relat Cancer 2021; 28: 549–561.

  49. Dromain C, Sundin A, Najran P, et al. Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability. Neuroendocrinology 2021; 111: 831–839.

  50. Michl P, Löhr M, Neoptolemos JP, et al. UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. United European Gastroenterol J. Epub ahead of print 25 August 2021. DOI: 10.1002/ueg2.12123.